India-US Trade Deal Talks Hit Plateau, Sitharaman Says 
Flavio Bolsonaro, Lula Head to Brazil Presidential Runoff 
DeepSeek Seeks $12 Billion Funding Round Backed by Tencent, CATL 
Schneider Electric to Buy PTC in $22.6 Billion Deal 
Zcash NU7 Testnet Cuts Block Time to 25 Seconds 
Fairshake Backs 32 Pro-Crypto House Candidates 
Iran Keeps Strait of Hormuz Closed as War Talks Stall 
OKXICE Files for 24/7 Tokenized US Stock Trading 
US DOT Ends Airline Privacy Review Without Enforcement 
Russia Strikes Kyiv Bridge as Ukraine Infrastructure Attacks Escalate 
US Army Tests Counter-Drone Technology Along Mexico Border 
Revolut Challenges Europe’s Banking Giants as Global Growth Accelerates 
Bosnia Election Puts EU Bid and Foreign Influence in Focus 
Nicaragua Withdraws From Central American Parliament 
OpenAI, Anthropic Back Mandatory AI Breach Reporting in Australia 
Supreme Court Takes Up Exxon, Suncor Climate Case 
Yemen Launches Major Offensive to Retake Houthi-Held Areas 
Add as a preferred source on Google
Becton Dickinson and Co. (NYSE: BDX) has agreed to invest $3 billion to expand medical-product manufacturing in the United States, President Donald Trump announced Tuesday, as his administration seeks to strengthen domestic healthcare supply chains.
Trump said more than $1 billion of the planned investment will be directed toward Nebraska, where Becton Dickinson, commonly known as BD, intends to increase production of essential medical supplies. The expansion will include syringes, needles and other healthcare products, with some needles manufactured using U.S.-produced steel.
BD had not immediately issued a statement regarding Trump's announcement or responded to requests for comment.
The president linked the $3 billion commitment to his administration's proposed tariffs on imported medical devices. Trump said those tariffs are expected to take effect by the end of the year as part of a broader effort to encourage manufacturers to shift production to the United States.
The White House separately announced that BD will invest $110 million to expand production of prefillable syringes at its facility in Columbus, Nebraska. The project is expected to create approximately 120 jobs and comes on top of an earlier $35 million investment at the same manufacturing site.
The latest commitment underscores the Trump administration's push to reduce U.S. dependence on foreign-made medical products considered critical to the country's healthcare system. Increasing domestic production of syringes, needles and other supplies could help strengthen supply-chain resilience while supporting American manufacturing jobs.
Becton Dickinson is one of the world's largest medical technology companies, producing a broad range of devices and healthcare products used by hospitals, laboratories and other medical providers.
The company has also been reshaping its business portfolio this year. In February, BD completed the separation of its Biosciences and Diagnostic Solutions operations into Waters, allowing the medical technology company to focus more closely on its remaining businesses and manufacturing priorities.
The new $3 billion U.S. investment represents a significant expansion of that strategy as Washington increases pressure on healthcare manufacturers to bring more production onshore.
